Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Strongbridge Biopharma plc (SBBP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/05/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
10/29/2020 8-K Asset disposition, Quarterly results
Docs: "Rare Endocrine Franchise: RECORLEV® ● On September 8, 2020, Strongbridge reported positive and highly statistically significant top-line results from the Phase 3 LOGICS study, which met its primary and secondary endpoints. Additionally, RECORLEV was generally well-tolerated with a safety and tolerability profile comparable to the profile observed in the Phase 3 SONICS study. ● The Company is on-track to submit a New Drug Application for RECORLEV to the U.S. Food & Drug Administration in the first quarter of 2021; if approved, the launch of RECORLEV is anticipated in the first quarter of 2022, following a projected 10-month PDUFA review cycle. Rare Neuromuscular Franchise: KEVEYIS ® ● The Company achieved KEVEYIS net product sales of $8.1 million for the third quarter ende..."
08/04/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports First Quarter 2020 Financial Results and Provides Corporate Update ~ Phase 3 LOGICS Study of RECORLEV® Reaches 41 of 42 Targeted Study Participants Completing the Randomized Withdrawal Phase; One Additional Patient Currently in the Randomized Withdrawal Phase and One Other Patient Scheduled to be Randomized Imminently ~"
02/25/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
07/31/2019 8-K Quarterly results
05/01/2019 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update"
02/26/2019 8-K Quarterly results
10/31/2018 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
08/08/2018 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update",
"Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEVÔ for the Treatment of Endogenous Cushing's Syndrome",
"Presentation of Strongbridge Biopharma plc"
05/10/2018 8-K Quarterly results
Docs: "Strongbridge Biopharma plc Reports First Quarter 2018 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy